%0 Journal Article
%T CD14在脓毒症中的最新进展
%A 邵珍珍综述
%A 李泉
%A 审校
%J 同济大学学报(医学版)
%D 2016
%R 10.16118/j.1008-0392.2016.06.027
%X 脓毒症临床表现多样,是创伤、烧伤、感染、休克等临床危急重患者的常见严重并发症,其发病率和死亡率一直居高不下。前期研究发现,脂多糖结合蛋白(lipopolysaccharide binding protein, LBP)和白细胞分化抗原CD14(Leukocyte differentiation antigen, CD14)通过识别革兰阴性杆菌产生的内毒素,在脓毒症的发病过程中起关键作用。本文通过综合分析CDl4在脓毒症中的致病机理,探讨其在脓毒症诊断及治疗中的潜在临床价值。</br>Sepsis is a life-threatening disease responsible for high morbidity and mortality, which is initiated by varying conditions including trauma, burn and infection. Studies have revealed that lipopolysaccharide binding protein(LBP) and Leukocyte differentiation-14 antigen(CD14) recognize lipopolysaccharide(LPS) of gram-negative bacteria and trigger inflammatory response, playing a fundamental role in the development of sepsis. This review focuses on the role of CD14 in pathogenesis of sepsis and suggests that CD14 may be used as a potential biomarker for diagnosis and treatment of sepsis
%K 脓毒症 CD14 脂多糖结合蛋白 内毒素&lt
%K /br&gt
%K sepsis CD14 lipopolysaccharide binding protein endotoxin
%U http://tjyxxb.cnjournals.cn/ch/reader/view_abstract.aspx?file_no=20160627&flag=1